Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 1Heart Failure 1Carcinoma, Hepatocellular 1Arrhythmias, Cardiac 1Anemia 1

Interventions

Epoetin Alfa 38Darbepoetin alfa 30epoetin beta 10peginesatide 3luspatercept 3hematide 3ACE-011 3telapristone acetate 2ferric carboxymaltose 2Erythropoietin 2AP 1903 reagent 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2roxadustat 1iron isomaltoside 1000 1ferrous sulfate 1ferric gluconate 1continuous erythropoietin receptor activator 1angiotensin I (1-7) 1Sugars 1Standard of Care 1Solutions 1Population Groups 1NOX-H94 1Lenalidomide 1LY2787106 1Iron-Dextran Complex 1Injections 1Infliximab 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anemia × Population Groups × Clear all
NCT06737081 2024-12-17

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 2 Recruiting
60 enrolled
Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡